Rituximab
Code | Size | Price |
---|
TAR-T9910-1mg | 1mg | £257.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T9910-5mg | 5mg | £518.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T9910-10mg | 10mg | £725.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T9910-25mg | 25mg | £1,066.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Rituximab anti-CD20) is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM.
CAS:
174722-31-7
Formula:
0
Molecular Weight:
148 kDa
Purity:
0.98
SMILES:
0
References
Chow KU, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica. 2002 Jan;87(1):33-43.
Schliemann C, et al. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood. 2009 Mar 5;113(10):2275-83.
Du J, et al. Structural basis for recognition of CD20 by therapeutic antibody Rituximab. J Biol Chem. 2007 May 18;282(20).
Cartron G, et al. Pharmacokinetics of rituximab and its clinical use: thought for the best use Crit Rev Oncol Hematol. 2007 Apr;62(1):43-52.
George J. et al. Rituximab: mechanism of action.Semin Hematol. 2010 April ; 47(2): 115?123.